Seattle biotech Alpine Immune Sciences lands $48M in Series A funding

Seattle's Alpine Immune Sciences has landed $48 million in Series A funding, an amount that the preclinical company expects to get it through clinical trials of its cancer and autoimmune disease drugs. OrbiMed Advisors, a medical and health care investment firm with offices in San Francisco and New York, led the round. Also taking part were Frazier Healthcare Partners and Alpine BioVentures, the investment company that created Alpine Immune Sciences, or AIS. Mitch Gold, a managing partner at Alpineā€¦
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news